A Randomized Phase II Trial of Carboplatin-Paclitaxel With or Without Ramucirumab in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma
Latest Information Update: 28 Mar 2025
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Ramucirumab (Primary)
- Indications Malignant thymoma
- Focus Therapeutic Use
Most Recent Events
- 25 Mar 2025 Status changed from active, no longer recruiting to completed.
- 28 Nov 2024 Planned primary completion date changed from 1 Dec 2024 to 15 Mar 2025.
- 05 Jul 2024 Planned End Date changed from 30 Nov 2024 to 1 Jun 2025.